(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Neuphoria Therapeutics's earnings in 2025 is N/A.On average, 1 Wall Street analyst forecast NEUP's earnings for 2026 to be -$3,477,930, with the lowest NEUP earnings forecast at -$3,477,930, and the highest NEUP earnings forecast at -$3,477,930. On average, 1 Wall Street analyst forecast NEUP's earnings for 2027 to be -$2,274,754, with the lowest NEUP earnings forecast at -$2,274,754, and the highest NEUP earnings forecast at -$2,274,754.
In 2028, NEUP is forecast to generate -$2,556,748 in earnings, with the lowest earnings forecast at -$2,556,748 and the highest earnings forecast at -$2,556,748.